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Abstract
The molecular mechanisms involved in acquiring opiate-related associative memories are
largely unknown. One neural region implicated in the formation of opiate-related memories is
the basolateral nucleus of the amygdala (BLA). Transmission through dopamine (DA) receptors
within the BLA controls the formation of opiate-related reward memories (Lintas et al., 2011;
Lintas et al., 2012). Specifically, transmission through DA D1 receptors controls opiate reward
memory formation in animals that are previously naïve to opiate exposure. However, once opiate
dependence and withdrawal are present, intra-BLA DA-mediated control of opiate reward
memory processing switches to a DA D2 receptor substrate. These findings demonstrate a DA
receptor D1D2 functional switching mechanism controlling the acquisition of opiate-related
memories. However, it is unclear what are the underlying molecular substrates controlling the
transition from a D1 to a D2 receptor-dependent memory mechanism are, and how chronic
opiate exposure controls the process. Using a Pavlovian Place Preference (CPP) paradigm
combined with molecular protein analyses, we tested the hypothesis that D1 and D2-like
receptors in the BLA control the acquisition of opiate reward memory through modulation of
intracellular phosphorylated MEK and phosphorylated CaMKII levels, respectively. We report
that intra-BLA blockade of MEK inhibits opiate reward memory acquisition in previously
opiate-naïve but not opiate dependent/withdrawn animals. Conversely, inhibition of CaMKII
phosphorylation blocks the acquisition of opiate-related reward memory only in opiate
dependent/withdrawn animals. Furthermore, chronic opiate exposure down-regulates the
phosphorylation of MEK, and dramatically down-regulates expression levels of CaMKII. Our
findings demonstrate a novel opiate exposure-state dependent molecular switch within the BLA
controlling the formation of opiate-related reward memories.
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1.

Introduction

1.1

Opiate Addiction in Canada
Opiate addiction is a complex pathological disorder of learning and memory that

represents a pervasive healthcare issue across Canada and most of North America (Fischer,
Patra, Cruz, Gittins, & Rehm, 2008; Nosyk et al., 2012). Addiction is characterized by a
transition from voluntary to persistent, compulsive drug use even in the face of adverse physical,
psychological, and social consequences associated with continued drug use. It is also
characterized by a high likelihood for relapse even after extended periods of successful
abstinence (Everitt et al., 2008; Trigo, Martin-García, Berrendero, Robledo, & Maldonado,
2010). The extremely potent compulsive thoughts focused on obtaining drugs, no matter the cost,
and the high rate of relapse following recovery, not only adversely affect the individual suffering
from the disorder but also society as a whole. The societal costs associated with opiate abuse and
dependence includes health-related expenses, law enforcement costs, and loss of productivity
costs. In actual dollar amounts, the cost to society for each addict over a lifetime can range, on
average, anywhere from $736,800 to over $1,000,000 (Nosyk et al., 2012). As such, opiate
addiction represents a costly, chronic, intermittently recurring disorder treated primarily with a
therapeutic procedure that is only minimally effective.

Methadone maintenance treatment (MMT) is currently the most common form of
treatment offered to people suffering from opiate addiction. However, research has shown
repeatedly that MMT is not especially effective (Nosyk et al., 2012; Ward, Hall, & Mattick,
1999). Although MMT reduces the frequency of heroin use and risk of contracting diseases

2
transferrable by needle sharing, such as HIV and Hepatitis C, it has a high rate of attrition and
non-compliance. Furthermore, the MMT treatment itself can be dangerous, and the facilities and
supplies required to sustain the treatment are quite expensive (S. Johnson, Macdonald, Cheverie,
Myrick, & Fischer, 2012; Nosyk et al., 2012; Ward et al., 1999). A number of alternative
treatment strategies for opiate addiction have been introduced over the years some of which have
yielded moderate success in reducing societal costs related to addiction but none of which relieve
the core, underlying neurobiological mechanisms sustaining the opiate addiction cycle. Decades
of neuroscience research in both human and animal models of opiate addiction suggest that the
primary feature of the opiate addiction process involves the triggering of intrusive and
compulsive associative memories linked to environmental cues associated with the rewarding
effects of opiates. The activation of these associative memories in turn, drives drug seeking
behavior in both humans and other animals. These memories, triggered by drug-related cues in
the environment, seem to take precedence over all other cogent thought and decision-making and
are extremely resistant to extinction. However, it is still unclear how drug-related sensory
experiences gain their tremendous incentive salience, how they maintain their saliency status, or
what the most effective therapeutic procedure would be to extinguish these memories. The high
prevalence of opiate addiction across North America, the high financial burden associated with
opiate addiction, and the low to moderate success rate of current treatments, speak to the urgency
of basic neurobiological opiate addiction research and the development of more effective
pharmacotherapeutic treatments.

1.2

Reward Learning and the Mesocorticolimbic System
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Recent theories of drug addiction underscore the importance of neural plasticity, learning,
and memory formation, recall, and extinction as critical processes underlying the persistence of
chronic opiate abuse. Opiates are highly euphorigenic and produce potent associative memories
linked to the drug taking experience. In fact, the ability of opiate-related memory cues to trigger
opiate craving is a primary factor underlying persistent opiate relapse, even after years of
successful abstinence. It is unclear how, at the level of the individual neuron, these drug-related
changes take place. Although, it is well documented that chronic drug use causes long-lasting
changes in neuronal structure and function within the neural circuitry involved in encoding
reward-related and/or emotionally salient memories (Robinson & Berridge, 1993). That circuitry,
referred to as the mesocorticolimbic system (MCLS), consists of a series of interconnected
structures including the ventral tegmental area (VTA), the basolateral nucleus of the amygdala
(BLA), the pre-frontal cortex (PFC), and the nucleus accumbens (NAc) (see Figure 1). Each of
these structures, individually and in concert with one another, contributes to the ascription of
incentive salience to sensory stimuli and to the formation of associative memories that drive
drug-seeking behaviours.
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Figure Caption 1:
Proposed model for the formation of associative memories within the MCLS.
Proposed model for the formation of opiate-related reward memory. Opiates bind to μ-opiate
receptors on GABAergic interneurons in the VTA removing GABAergic inhibition over local
DA neurons thereby facilitating DAergic release to the BLA and NAc. The increased DA
concentration causes a release of GABAergic inhibition over local pyramidal neurons while
simultaneously stimulating integration of associative signaling from the sensory cortex.
Associative memories, between the motivational effects of opiates (VTA DA signal) and sensory
information from convergent cortical sensory inputs, form in BLA neuronal populations.
GLUergic release from the BLA towards the mPFC and NAc become active and NAc GLUergic
projections to motor cortex facilitated.
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1.2.a The Ventral Tegmental Area
DAergic projections within the MCLS originate from DAergic neurons in the VTA and
terminate throughout the MCLS. DAergic projections are involved in encoding the primary
rewarding effects of opioids but not the subjective experience of drug craving following
abstinence (Breiter et al., 1997). Put another way, the VTA is the primary area in which the
rewarding "high" of drugs of abuse are processed. As an example, Olmstead and Franklin (1997)
tested the rewarding effects of opiates when administered into various regions of the central
nervous system. They reported that direct, intra-VTA administration of morphine elicits
observable drug seeking behaviors while direct administration of morphine to other areas of the
MCLS failed to produce comparable motivational effects. The VTA is an area rich in µ-opiate
receptors making it a primary target for the binding of opioid molecules. Consequently, opiates
achieve their euphoric effects by binding to -opiate receptors in the VTA, which are associated
with ‘non-DA’, GABAergic interneurons. Since -opiate receptors are inhibitory in nature, their
activation in turn inhibits the inhibitory GABAergic inputs to the VTA DA neurons, leading to
the disinhibition, and indirect activation of the VTA DA neurons. Indeed, studies show that
pharmacological blockade of µ-opiate receptors within the VTA impairs the encoding of the
rewarding effects of opiates (Olmstead & Franklin, 1997).

Binding of opioids to µ-opiate receptors facilitates DAergic output from the VTA to all
of the other areas of the MCLS and facilitates an increase in the overall concentration of DA
throughout the MCLS (Adinoff, 2004; Ford, Mark, & Williams, 2006). These DAergic
projections from the VTA excite neighboring structures (see Figure 1). Specifically, DA neurons
located in the VTA are dynamically regulated by local GABAergic inter-neurons (S. W. Johnson
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& North, 1992; Klitenick, DeWitte, & Kalivas, 1992; Steffensen et al., 2006). When exogenous
opioids are introduced into the system, opioid molecules bind to opiate receptors located on
GABAergic cells, releasing the GABAergic inhibition over DA cells (S. W. Johnson & North,
1992; Klitenick et al., 1992), and indirectly facilitating DAergic release to the other areas of the
MCLS (De Vries & Shippenberg, 2002). This DAergic neurotransmission plays an important
role in modulating neuronal plasticity within the system and smoothes the process of experiential
learning.

1.2.b The Basolateral Nucleus of the Amygdala
The BLA receives DAergic projections from the VTA. These DAergic projections
indirectly modulate neuronal plasticity within the BLA while the BLA simultaneously receives
neural signaling from areas of the sensory cortex (area Te3) (Bissière, Humeau, & Lüthi, 2003;
Kröner, Rosenkranz, Grace, & Barrionuevo, 2005; Rosenkranz & Grace, 2003). The increase in
DA concentration in the BLA facilitates GLUergic output from the BLA to areas such as the
NAc and PFC (Kröner et al., 2005; Rosenkranz & Grace, 2003). Thus, the BLA is an ideal area
for the integration of opiate-mediated salience signaling from the VTA with concurrent sensory
experiences leading to the formation of experience-related associative memories. In keeping with
this idea, studies have demonstrated a critical role for the BLA in the formation of associative
memories that carry emotional significance. For instance, although opiates hold no rewarding
effect when delivered directly into the BLA (Olmstead & Franklin, 1997) inactivation of the
BLA causes a deficit in the formation of emotionally-relevant opiate-related conditioned
associations (Fuchs & See, 2002). In other words, when the BLA is inactive the animal is unable
to learn a simple classically conditioned association between a rewarding or aversive stimuli and
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an external sensory experience temporally paired with it. Similarly, activation of the BLA
promotes the formation of associative memories (Adinoff, 2004; Grace & Rosenkranz, 2002;
Lintas et al., 2012). Presumably then, the BLA is associated with the acute formation of
associative memories within the MCLS. However, the molecular mechanism(s) by which the
BLA is able to integrate opiate-related euphoria encoded by the VTA and sensory signaling from
sensory cortices, occurring in tandem, to form potent associative drug-related memories is
unclear.

1.2.c

The Pre-Frontal Cortex
The pre-frontal cortex (PFC) is an area important for higher order cognition, decision-

making, and for regulating subcortical structures. Similarly, within the context of experiencebased learning and memory, the PFC plays an important role in regulating the activity of its
neighboring structures within the MCLS such as the BLA. However, the PFC is a very large
region with many different subdivisions all structurally and functionally distinct from one
another. The medial pre-frontal cortex (mPFC) is the portion of the PFC implicated for its' role in
regulating the formation, maintenance, and extinction of associative memories. The mPFC
includes the pre-limbic cortex (PLC) and the infra-limbic cortex (ILC) with the PLC located
superior to the ILC (Paxinos & Watson, 2005).

As mentioned previously, the BLA is important for acute formation of associative
memories. The formation of emotionally salient associative memories within the BLA depends
upon maintenance of a delicate balance of reciprocal interconnections between the BLA and the
mPFC. The mPFC receives DAergic neurotransmission from the VTA and GLUergic
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transmission from the BLA. In turn the mPFC sends inhibitory GLUergic projections back to the
BLA (Grace & Rosenkranz, 2002; Peters, Kalivas, & Quirk, 2009; Rosenkranz & Grace, 2001).
It is through these neural signaling pathways that the mPFC and BLA dynamically modulate
each other's activity to control the formation, recall, and extinction of associative memories.

The projections from the mPFC to the BLA are inhibitory in nature, thereby influencing
the likelihood that an associative memory will be formed (Peters et al., 2009; Rosenkranz &
Grace, 2001, 2003). For example, inhibition of the PLC, within the mPFC, dramatically
potentiates the saliency of normally non-salient stimuli and facilitates the formation of opiaterelated associative memories (Bishop, Lauzon, Bechard, Gholizadeh, & Laviolette, 2011;
Lauzon, Ahmad, & Laviolette, 2011). Once a memory has been encoded, neuronal activation
within the mPFC influences recall and extinction of the memory (Grace & Rosenkranz, 2002;
Peters et al., 2009; Sun et al., 2011; Sun & Laviolette, 2012). However, chronic drug use
modifies the DAergic transmission throughout the MCLS, including transmission between the
mPFC and BLA thus altering the balance of interplay between the mPFC and BLA as well as the
formation of associative memories dependent on the mPFC and BLA.

1.2.d. The Nucleus Accumbens
The nucleus accumbens (NAc) is responsible for translating neural signaling from other
areas of the MCLS into appropriate behavioral responses, and as such, is often referred to as a
“limbic-motor interface” (Ambroggi, Ishikawa, Fields, & Nicola, 2008). It has two important
subdivisions, the NAc shell, and core (NAcS, NAcC). The main function of the NAcS is to
strengthen stimulus-drug associations while the NAcC is responsible for the expression of drug-
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seeking behaviour associated with the stimulus-drug association (Di Chiara, 2002; Di Chiara et
al., 2004). For instance, DA concentration within the NAcS increase upon introduction of salient
sensory stimuli and this increase is associated with a decrease in latency to learn a reinforcement
contingency such as a lever press for reward (Beyene, Carelli, & Wightman, 2010). Hence,
exposure to novel stimuli increases DA concentration within the NAcS and consequently
facilitates encoding of action-consequence relationships. In contrast, inactivation or ablation of
the NAcC results in a significant decrease in the number of lever presses an animal will make for
a given reward (Ambroggi et al., 2008). Thus, the NAcC is important for the expression of
reward-driven behaviors rather than the ability to learn a reinforcement contingency. Put another
way, the animal is able to learn the reward contingency but appears to be less motivated to
acquire the reward. For example, where a healthy animal may push a lever to get a food reward
ten times in one minute, an animal with a NAcC deficit may only push the lever four times.

Similar to the VTA, the NAc is rich in µ-opiate receptors and direct administration of
opiates to the NAcS elicits drug-seeking behavior (Olmstead & Franklin, 1997). Opiates achieve
their motivational effect by increasing the concentration of DA in the NAc through DAergic
input from the VTA (McDonald, 1991a, 1991b; Stuber et al., 2011). Blockade of DA
transmission within the NAc impairs expression of reward seeking behaviors (Ambroggi et al.,
2008; Nicola, Taha, Kim, & Fields, 2005). In addition, the NAc receives GLUergic inputs from
the BLA (McDonald, 1991a, 1991b; Stuber et al., 2011) which work in concert with DAergic
input from the VTA to facilitate the expression of drug seeking behaviors. Functionally, DA
transmission within the BLA strongly modulates neuronal activity specifically within the NAcS.
Thus, blockade or activation of DA D1 or D2 receptors directly within the BLA can either
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increase or decrease NAcS neuronal sensitivity to opiate administration (Lintas et al., 2011;
Lintas et al., 2012). Again, this BLA DA-mediated modulation of NAcS neuronal responsiveness
is dependent upon the opiate exposure history of the animal, with D1 receptors important only
when in an opiate-naïve state, and D2 receptors only important when in an opiate dependent and
withdrawn state (Lintas et al., 2011; Lintas et al., 2012). Blockade of DAergic or GLUeric
receptors within the NAcS attenuates drug-related neuronal activation and subsequent drugseeking behaviors (Ambroggi et al., 2008; Bassareo, Musio, & Di Chiara, 2011; Lecca,
Valentini, Cacciapaglia, Acquas, & Di Chiara, 2007; Lintas et al., 2011; Lintas et al., 2012).
Thus, the shell and core subdivisions of the NAc play an important role in translating cell
signaling within the MCLS into behavioral output. Once again, the introduction of exogenous
opiates into the system modifies the functionality of the NAc and thereby modifies the
behavioral output generated by cellular signaling within the MCLS.

All components of the MCLS, the VTA, BLA, PFC, and NAc, play important but
discrete roles in the formation and expression of drug-related behaviors. However, the ability of
each component to perform its role effectively often depends upon their interconnections
between one another. The introduction and chronic use of exogenous opiates modifies the
structure and function of individual neurons and their synaptic connections between one another
within the structures which make up the components of the MCLS. These neuronal and synaptic
modifications eventually translate into behavioral modifications, ultimately resulting in the
maladaptive compulsion to use drugs even in the face of adverse consequences. However, it is
unclear exactly how these modifications take place within and between neurons and it is unclear
how the changes are maintained on a long term basis. Thus, the opiate-related modifications in
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DA neurotransmission in the MCLS following chronic opiate use are a key target of research
studies attempting to answer those questions.

1.3

Opiate Reward Learning and Dopamine
Acute and chronic opiate use differentially modulate DAergic neurotransmission within

the MCLS (Berridge & Robinson, 1998; Laviolette, Nader, & van der Kooy, 2002; Self &
Nestler, 1998) making DA a key target of investigation in the opiate addiction literature.
Dopamine, often thought of as the "reward" neurotransmitter, conveys information about
rewarding stimuli, or events that may signal impending reward. However, there is extensive
evidence which would suggest that DA is important for conveying the "incentive salience" of
stimuli rather than their rewarding properties per se (Berridge & Robinson, 1998; De Vries &
Shippenberg, 2002; Robinson & Berridge, 1993). For instance, in the context of ordinary,
experience-based learning, DA concentration throughout the MCLS increases in response to
novel stimuli regardless of the rewarding or aversive valence of the stimulus (Adinoff, 2004;
Berridge & Robinson, 1998; Lamb et al., 1991). In addition, novel stimuli-related increase in DA
neurotransmission is attenuated following repeated exposure to the stimulus but increased once
again if the reward contingency associated with the stimulus is changed (Horvitz, 2000). These
studies indicate that regardless of the emotional valence of the stimuli (rewarding or aversive)
DA transmission is facilitated whenever a novel stimuli or event is encountered and decreases as
the stimuli becomes more familiar with repeated exposures.

Abnormalities in DA transmission are implicated in a number of neuropsychological
disorders including opiate addiction. Long-term opiate use alters the usual fluctuations in DA
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transmission initiated by novel experiences (Adinoff, 2004; Di Chiara, 2002; Volkow, Fowler,
Wang, Baler, & Telang, 2009). For example, whereas repeated exposure to previously novel
stimuli would normally decrease DA release, in the context of chronic opiate exposure there is
no decrease in DA transmission following repeated exposures. Abstinence from drug use
following extended periods of chronic opiate use results in a dramatic drop in DA concentration
throughout the MCLS and aversive somatic withdrawal symptoms (Di Chiara, 1999; Volkow,
Fowler, Wang, & Goldstein, 2002). This suggests that opiates alter DA transmission within the
MCLS to facilitate the allocation of attention and ascription of incentive salience to stimuli that
would otherwise hold little or no incentive salience. This dramatic boost in the motivational
salience of objects or events also results in a higher likelihood of the formation of associative
memories between the experience of drug use and the surrounding environment at the time of
use. The associative memories later serve as potent cues for reinstatement and/or relapse of drug
seeking behaviour following withdrawal and/or long term abstinence.

1.3.a DA D1-like versus D2-like Receptors
There are two broad families of DA receptors. These receptor subtypes are classified into
the ‘D1-like’ and ‘D2-like’ families of receptors. The D1 family (herein referred to as D1R)
includes the D1- and D5-type receptors and the D2 family (herein referred to as D2R) includes
the D2-, D3-, and D4-type receptors (Missale, Nash, Robinson, Jaber, & Caron, 1998; Vallone,
Picetti, & Borrelli, 2000). The two families of receptors are both G-protein coupled metabotropic
receptors with seven transmembrane domains. However, they are distinct from one another in
terms of their locations on neurons, which G protein subunit they couple to, and their influence
on two distinct intracellular downstream signaling cascades. D1R's tend to be located post-
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synaptically; they couple to the Gαs subunit, and activate the intracellular PKA/cAMP pathway.
D2R's, on the other hand, tend to be located pre-synaptically, as autoreceptors, and postsynaptically. D2R's couple to the Gαi/o subunit, and inhibit the PKA/cAMP pathway (Berke &
Hyman, 2000; Meador-Woodruff, Damask, & Watson, 1994; Vallone et al., 2000). However,
chronic stimulation of DA receptors through continuous drug use modifies the expression,
function, and binding affinity of D1R and D2R's on individual neurons and does so differentially
for each family of receptors (Bhargava & Gulati, 1990; Collins et al., 2011; Novak & Seeman,
2010; Volkow et al., 1993).

Numerous studies have reported dissociable roles for D1R and D2R's in relation to the
formation and expression of drug seeking behaviors depending upon the state of previous drug
exposure one is in at the time of encoding (Grieder et al., 2012; Lauzon, Bishop, & Laviolette,
2009; Laviolette, Lauzon, Bishop, Sun, & Tan, 2008; Lintas et al., 2011; Lintas et al., 2012).
Specifically, for animals in a previously opiate-naive state (PN), the ability to encode opiaterelated associative memories depends upon activation of D1R's in the BLA. Conversely, for
animals in an opiate-dependent/withdrawn state (DWD), activation of D2R's in the BLA is
required for the formation of opiate-related associative memories (Lintas et al., 2011; Lintas et
al., 2012). The reason behind the functional dissociation between D1R and D2R's is not clear
although there is some indication that the distinct intracellular signaling pathways initiated by the
activation of D1R and D2R's may provide some explanation. For instance, Lintas and colleagues
(2011, 2012) demonstrated that in PN animals the D1R antagonist-mediated blockade of
associative opiate-reward memory can be rescued by co-administration of a cyclic-AMP/PKA
activator. Hence, by restoring the activation of cyclic-AMP/PKA normally initiated by D1R
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activation, the formation of the associative memory was able to occur as it normally would.
Further, in DWD animals a D2 antagonist-mediated blockade of associative memory can be
rescued by co-administration of a cyclic-AMP/PKA antagonist (Lintas et al., 2011). Taken
together this research suggests that the intracellular signaling pathways altered by the activation
of D1 and D2 receptors activation may reflect their functional differences under acute versus
chronic morphine exposure states. Even more importantly, considerable evidence points to
functional linkages between the D1-like receptors with downstream signaling of mitogenactivated protein kinase (MAPK) and between D2-like receptors with downstream signaling of
the calcium/calmodulin-dependent kinase (CaMK) signaling pathways.

1.4

Intracellular Signaling Cascade Kinases Linked to D1 or D2 Receptor Transmission
Intracellular signaling cascades are important for transducing extracellular signaling to

the relevant intracellular effecter sites regulating cellular processes including gene synthesis and
transcription, neurotransmitter synthesis, packaging, and release, as well as growth and pruning
of synaptic connections, and cell death. There are many extracellular as well as intracellular
variables which work together to determine which signaling cascades will be activated and what
the consequences of their activation will be for cell structure and function. Two signaling kinases
critical for learning and the formation of synaptic LTP are the mitogen-activated protein kinase
pathway (MAPK) and the calcium/calmodulin-dependent protein kinase pathway (CaMK).
MAPK and CaMK are functionally interconnected with D1R and D2R's, respectively (Acquas et
al., 2010; Fricks-Gleason & Marshall, 2011; Gangarossa et al., 2011; Gu & Yan, 2004; Ibba et
al., 2009; Liu et al., 2009; Novak & Seeman, 2010; O'Sullivan et al., 2008).
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The D1R-related MAPK pathway is a well characterized intracellular signaling pathway
which includes the protein kinases MEK(1/2) and ERK(1/2) in its chain of signaling proteins
(Seger & Krebs, 1995). The MEK kinase is located in the cytoplasm and is phosphorylated by
tyrosine (Tyr) and serine/threonine (Ser/Thr). When Tyr and Ser/Thr phosphorylate at the cell
membrane they in turn phosphorylate MEK farther down the signaling chain in the cytoplasm of
the neuron (Anderson, Maller, Tonks, & Sturgill, 1990). Once phosphorylated, MEK can
autophosphorylate until its eventual deactivation via Tyr phosphatase (CD45) or protein-Ser/Thr
phosphatase 2A (PP2A) (Anderson et al., 1990). When MEK phosphorylates and is in its active
state it is able to phosphorylate downstream targets in the signaling cascade.

An important consequence of MEK phosphorylation is facilitation of the encoding of new
memories. As an example, an up-regulation in pMEK levels during the encoding phase of
learning and a drastic impairment in the ability to encode new memories when MEK
phosphorylation has been artificially inhibited has been reported (Alvarez-Jaimes, FelicianoRivera, Centeno-González, & Maldonado-Vlaar, 2005; Fricks-Gleason & Marshall, 2011; Kelly,
Laroche, & Davis, 2003; Lin, Wang, Ji, & Yu, 2010). Interestingly, activation of D1R's at the
cell membrane is associated with increased levels of phosphorylated MEK (pMEK1/2, pERK1/2)
during the encoding phase of associative learning. Conversely, blockade of D1R's or blockade of
MEK phosphorylation impairs encoding of associative memories (Alvarez-Jaimes et al., 2005;
Fricks-Gleason & Marshall, 2011; Kelly et al., 2003; T. Li et al., 2010; Lintas et al., 2011; Pan,
Zhong, Sun, & Liu, 2011). Therefore, an important link exists between the activation of D1R's
and the phosphorylation of MEK during the formation of associative memories.
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Acute as well as continuous exposure to a wide variety of drugs of abuse, including
opiates, varies pMEK levels and D1R's expression within the MCLS (Bhargava & Gulati, 1990;
Bilecki et al., 2005; Lin et al., 2010; Ma, Zheng, Powell, Jhamandas, & Quirion, 2001).
Expressly, acute exposure to caffeine, ethanol, cocaine, and morphine all substantially increase
pMEK levels throughout many regions of the brain (Acquas et al., 2010; Bilecki et al., 2005;
Ferrer-Alcón, García-Fuster, La Harpe, & García-Sevilla, 2004; Fricks-Gleason & Marshall,
2011; Ibba et al., 2009; Ma et al., 2001; Seo et al., 2008). In addition, exposure to drug-paired
cues, rather than the drug itself, also increases pMEK levels. Also of interest is the fact that
pharmacological blockade of D1R's can prevent drug exposure-induced increases in pMEK
levels and suppression of MEK phosphorylation impairs the formation of drug-related
associative memories (Acquas et al., 2010; Fricks-Gleason & Marshall, 2011; Ibba et al., 2009;
Z. Li et al., 2011). Therefore, not only are pMEK levels increased during the formation of new
memories and in synchrony with D1R's, but pMEK levels are also modified by drug exposure
and exposure to drug-paired cues. The implications of these drug-related modifications in pMEK
levels for the acquisition of drug-related associative memories within the BLA are unclear at this
point. However, research to date suggests that pMEK does play an important role in the
formation of drug-related memories, and that role may differ depending upon the drug-exposure
state one is in at the time of memory encoding.

The D2R-related calcium/calmodulin-dependent protein kinase (CaMKII) pathway is also
important for the formation of new memories (Fink & Meyer, 2002; Frankland, O'Brien, Ohno,
Kirkwood, & Silva, 2001; Lisman, Schulman, & Cline, 2002). An increase in intracellular
concentration of calcium (Ca2+) promotes binding of calmodulin to the kinase on its catalytic
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domain (Thr286) and transforms CaMKII into its active phosphorylated state. Once in this state,
CaMKII can autophosphorylate independent of Ca2+/calmodulin until its eventual
dephosphorylation by phosphatase (Fink & Meyer, 2002).

The active form of CaMKII, phosphorylated CaMKII (pCaMKII), phosphorylates its
neighboring proteins in the CaMK pathway leading to modifications in neuronal structure and
function (Frankland et al., 2001; Lisman et al., 2002; Shen & Meyer, 1999). Through this chain
of phosphorylation, pCaMKII is able to influence the formation of new memories in a similar
fashion as pMEK. For instance, pCaMKII levels, similar to pMEK levels, are increased during
the formation of new memories while pharmacological blockade of pCaMKII impairs the
formation of new memories (Fan, Wang, Qiu, Ma, & Pei, 1999; Lauzon et al., 2011; Narita et al.,
2004). However, in contrast to pMEK, pCaMKII level regulation is closely associated with the
activation of D2R's such that D2R activation leads to increased pCaMKII levels (Gu & Yan,
2004; Liu et al., 2009; Novak & Seeman, 2010).

Acute and chronic drug use differentially modifies the expression of D2R's and in a
comparable fashion; acute and chronic drug use dynamically modulates pCaMKII levels
(Christian, Alexander, Diaz, Robinson, & McCool, 2012; Frankland et al., 2001; Lisman et al.,
2002; Lou, Zhou, Wang, & Pei, 1999; Lu, Zeng, Liu, & Ceng, 2000; Wang & Wang, 2006;
Wanjerkhede & Bapi, 2008). Where acute opiate use frees Ca2+ from intracellular cystolic stores
and increases pCaMKII levels for a short period of time, chronic opioid use results in a much
longer lasting up-regulation of pCaMKII levels (Christian et al., 2012; Fan et al., 1999;
Greenstein, Novak, & Seeman, 2007; Lou et al., 1999; Seo et al., 2008; Wang & Wang, 2006).
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Evidence suggests that this long lasting up-regulation of pCaMKII levels contributes to the
expression of drug tolerance whereby individuals require increased doses of the drug in order to
achieve the subjective experience of drug-related euphoria (Fan et al., 1999; Wang & Wang,
2006). In fact, amphetamine sensitized rats, a model often used to mimic human behaviors such
as hyperactivity and impulsivity characteristic of people with drug addictions, display an upregulation in pCaMKII levels (Greenstein et al., 2007).

Therefore, pCaMKII not only assists in the development of new memories, and does so in
synchrony with D2R activation, but it also plays a role in the development and persistence of
drug seeking behaviors. Much of the research to date concerning drug-related modulation of
pCaMKII levels has focused on regions of the brain other than the amygdala. As a result, the role
of pCaMKII in modulating neuronal plasticity within the BLA is largely unclear. However, the
fact that CaMKII phosphorylation is important for learning and memory and the evidence
suggesting that pCaMKII levels are affected by chronic drug use provide a compelling platform
for speculating about its role in drug-related learning and memory. For instance, pCaMKII may
modulate the formation of associative memories in the BLA and may do so differentially
depending on the drug-exposure state one is in at the time of encoding of the associative
memory.

1.5

Research Purpose and Hypotheses
We have previously reported identification of a novel opiate-exposure-state dependent

functional switch between DA D1R and D2R's in the acquisition of opiate-related reward
memories in the BLA (Lintas et al., 2011). However, we were not able to characterize how this
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switch was accomplished or what intracellular mechanisms might have been contributing to the
change. Research suggests that phosphorylation of MEK and CaMKII, following DA D1R and
D2R activation, respectively, may mediate the functional switch occurring at the level of the DA
receptors. The overarching aim of the experiments conducted in this research project were
to:
1. Determine the extent to which pMEK and pCaMKII are important for the
formation of associative opiate-related memories in the BLA
2. Determine the extent to which pMEK and pCaMKII's functional roles vary based
on opiate-exposure state
3. Determine the extent to which their roles depend upon activation of D1R and D2Rs

It was predicted, that the formation of associative memories depends upon increased
intra-BLA pMEK levels in opiate-naive animals and increased intra-BLA pCaMKII levels in
opiate-dependent/withdrawn animals. Further, we hypothesized that increased expression of
pMEK and pCaMKII would reflect D1R and D2R activation, respectively.

2.

Materials and Methods
This project included 23 independent experimental groups. Each group consisted of N=6-

8 adult male Sprague-Dawley (Charles River Canada) rats. In the following section, the materials
and methods used in this project including surgical and histological procedures, drug treatments,
behavioral paradigms, and statistical analysis are discussed.

2.1

Surgical Procedures
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Male Sprague-Dawley rats (Charles River, 350-400g at the start of the experiments) were
anaesthetized with a ketamine (80 mg/ml) xylazine (6 mg/ml) mixture and placed into a
stereotaxic device. Stainless steel guide cannulae (22 gauge; Plastics One) were bilaterally
implanted into the brain regions of interest using the following stereotaxic coordinates (in mm).
For the BLA (0˚ angle): from bregma AP -2.6, L ±5.0; from the dural surface, V -7.2. For the
VTA (10˚ angle): from bregma, AP -6.0, L ±2.6; from the dural surface, V -8.0. The cannulae
were secured using stainless steel screws and dental acrylic. Following the completion of
experiments, animals were anesthetized and intracardially perfused first with isotonic saline and
then with 10% formalin. Brains were then removed from the skull and placed in 10% formalin in
the fridge over night and transferred to a formalin-sucrose solution for long-term storage in the
fridge for at least 48 hours before sectioning. The brains were sectioned using a cryostat, at -30˚
Celsius, into 40μm slices and mounted onto microslides. The sections were stained with Cresyl
violet and the BLA and VTA cannulae placements were verified using light microscopy
according to the anatomical boundaries defined by Paxinos and Watson (2005). Any animals
with cannulae placements outside of the BLA and/or VTA were excluded from statistical
analysis.

2.2

Drug Treatments
The drugs used in this project included a MEK inhibitor (UO-126, Tocris), a CaMKII

inhibitor (KN-62, Tocris), a DA D1 receptor agonist (SKF-81297, Tocris), a DA D2 receptor
agonist (Quinpirole, Sigma), morphine (morphine hydrochloride, MacFarlane Smith), and heroin
(diacetylmorphine, MacFarlane Smith). All drugs were dissolved in filtered isotonic saline.
Bilateral intra-BLA or intra-VTA microinjections of 0.5μl per side took place over a 60 second
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time interval by means of plastic tubing connected to a 1l Hamilton micro-syringe. Following
which, an additional 60 second interval was allowed to ensure ample diffusion of the drugs from
the injector tip. All intra-BLA microinfusions (UO-126, KN-62, UO-126+SKF-81297, KN62+Quinpirole, saline vehicle) were performed immediately prior to systemic or intra-VTA
injections of morphine or saline. Following morphine or saline injection, animals were then
placed into one of the two randomly assigned place conditioning environments. For intra-BLA
DA receptor activation coupled with signaling kinase inhibition, the DA D1 agonist (SKF81297) and MEK inhibitor (UO-126) as well as the DA D2 agonist (Quinpirole) and CaMKII
inhibitor (KN-62) were co-administered. Both “supra-threshold” (5 mg/kg; i.p.) as well as “subthreshold” (0.05 mg/kg; i.p.) doses of morphine were employed throughout this project. All subthreshold doses were administered systemically while supra-threshold doses were administered
both systemically and intra-cranially. For systemic morphine administration experiments, a subthreshold dose does not normally produce a significant preference for a morphine-paired
environment, whereas a supra-threshold dose does produce a significant preference for a
morphine-paired environment (Bishop et al., 2011; Lintas et al., 2011; Lintas et al., 2012). For
experiments using intra-VTA morphine administration, a supra-threshold dose of intra-VTA
morphine (0.5 μg/0.5 μl) will produce a significant preference for the morphine-paired
environment (Laviolette, Gallegos, Henriksen, & van der Kooy, 2004; Laviolette & van der
Kooy, 2004; Nader & van der Kooy, 1997).

2.3

Conditioned Place Preference Paradigm
An motivationally neutral, and highly robust Pavlovian conditioned place preference

procedure (CPP) was used to train animals to associate the rewarding effects of morphine with
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one of two environments which differed in terms of colour, texture, and smell as described in
Laviolette and van der Kooy (2003), and Laviolette, Nader, and van der Kooy (2002). Following
recovery from surgery, animals were randomly assigned to an experimental group. All animals
were exposed to a pre-conditioning phase where they were placed into a motivationally neutral
grey box for 20 minutes. The following day, the 8 day conditioning phase commenced. The
conditioning phase took place in one of two 15 X 15 inch Plexiglas conditioning environments.
One environment was white with a wire-mesh floor covered in woodchips different from those in
the animals’ home cage. The other was black with a smooth Plexiglas floor wiped down with 2%
acetic acid immediately before the animal was placed into it. Thus, the conditioning
environments in the procedure differed in terms of visual, tactile, and olfactory cues. The type of
treatment received (saline or morphine) in each of the two environments were counterbalanced
such that each animal was randomly assigned to receive morphine in either the white or the black
environment and vice versa when receiving saline. Animals display no baseline preference for
either of these environments (Laviolette & van der Kooy, 2003).

During CPP conditioning experiments, animals received an equal number of morphineenvironment versus saline- environment pairings. Therefore, over the eight-day procedure
animals received four 30 minute morphine-environment pairings and four 30 minute salineenvironment pairings. Animals received three to five (opiate-naïve groups) or five to seven
(opiate-dependent groups) days to recover following the conditioning phase to ensure they were
in a “drug-free” state when tested. During testing, animals were placed on a narrow grey zone
that separates the white and black environments and the times spent in each of the black and
white environments were digitally recorded, using two stopwatches, and scored separately for
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each animal over a 10 minute test session. Animals must have had their front two paws and head
located in the environment in order for them to be considered within that environment (see
Figure 2A).

25
Figure Caption 2
Conditioned Place Preference Paradigm Diagram
(A) Standard CPP procedure: On day 1 all animals are placed into a neutral grey box for 20
minutes. On days 2 through 9 animals receive an injection (i.p.) of either saline (S) or morphine
(M) and are placed into either a white box or a black box for 30 minutes. Animals receive a total
of 4 saline and 4 morphine pairings fully counterbalanced over the 8 day conditioning phase. On
days 10 through 12 animals are left in their home cages to recover and to return to a “drug-free”
state. On day 13 animals are placed into the test box on the neutral grey strip for 10 minutes.
Animals may move freely between either side of the test box and the times they spend on either
side are recorded for later statistical analysis.
(B) Procedure used to create a state of opiate dependence and the standard CPP procedure when
animals are in an opiate-dependent/withdrawn state: On day 1 all animals are placed into a
neutral grey box for 20 minutes. On days 2 through 8 animals receive an injection
(subcutaneous) of heroin in their home cage (yellow box). On days 9 through 16 animals receive
an injection (i.p.) of either saline (S) or morphine (M) and are placed into either a white box or a
black box for 30 minutes. Animals receive a total of 4 saline and 4 morphine pairings fully
counterbalanced over the 8 day conditioning phase. On days 17 through 20 to 23 animals are left
in their home cages to recover and to return to a drug free state. On day 24 animals are placed
into the test box on the neutral grey strip for 10 minutes. Animals may move freely between
either side of the test box and the times they spend on either side are recorded for later statistical
analysis.
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2.3.a Induction of Opiate Dependence and Withdrawal
For experiments exploring behaviour in an opiate-dependent state, the animals were
conditioned/trained in a state of opiate dependency and withdrawal (DWD) as described in
(Bechara & van der Kooy, 1992; Laviolette et al., 2002; Laviolette & van der Kooy, 2004) (see
Figure 2B). Following recovery from surgery, animals were pre-conditioned for 20 minutes in a
neutral grey box. The following day the animals were given their first of seven daily 0.5 mg/kg
subcutaneous (s.c.) injections of heroin in order to create a state of heroin dependency. Animals
were then conditioned 21 hours after their last heroin injection. Behavioural signs of withdrawal
are evident in rodents following at least 16 hours of drug-abstinence (Bechara & van der Kooy,
1992). During the conditioning phase, heroin injections were administered as a maintenance dose
2.5 hours after the termination of each conditioning session. This 2.5 hour gap ensured animals
did not develop any associative memory between the conditioning environments and their daily
heroin injections. Over the course of the experiments, animals thus received a total of 15 heroin
injections (7 before conditioning, 8 during conditioning). The formation of opiate dependence
and subsequent signs of opiate-withdrawal observed following this regimen of heroin
administration is qualitatively similar to signs of dependence and withdrawal following a 3-week
regimen of morphine administration (Bechara & van der Kooy, 1992; Laviolette et al., 2002;
Laviolette & van der Kooy, 2004). However, by employing a shorter 7-day heroin regimen the
likelihood for formation of infections and blockages in in-dwelling cannulae was decreased
compared to a 3-week morphine regimen.

In experiments examining recovery from chronic opiate exposure animals were subjected
to a 7-day clearing period (drug free) after a 7-day heroin treatment as described above.
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Behavioural signs of withdrawal in rodents are no longer evident following a 7-day clearing
period (Bechara & van der Kooy, 1992). The clearing period was used to assure animals were
conditioned in a drug-free state. Following the induction of heroin dependence and the clearing
period, animals underwent the standard 8-day conditioning procedure, 3 to 5 day recovery
period, and testing phase.

2.4

Western Blot Procedure
Two groups of 8 animals were given 15 days of injections in order to mimic the number

of injections received during the formation of opiate dependence and withdrawal followed by
morphine place preference conditioning. The first group of 8 received daily saline injections and
the other 8 received daily heroin (0.5 mg/kg; s.c.) injections. Twenty-one hours following their
last injection, animals were sacrificed, their brains rapidly removed, and a micro-punch of the
amygdala isolated. The amygdalar tissue samples were then homogenized using a Dounce
homogenizer and protein isolated using RIPA lysis buffer containing a protease inhibitor tablet
(mini complete tablets; ROCHE) and phosphatase inhibitors (Calbiochem phosphatase inhibitor
cocktail set 4, Sigma phosphatase inhibitor cocktail 2). Following homogenization, the samples
were mixed with 2X Laemmli loading buffer and heated to 95 degrees Celsius for 5 minutes
prior to storage in a -80 degrees Celsius freezer until needed for Western blotting.

Twenty-five µg of protein from the control (PN) and treatment (DWD) samples were
loaded onto 12% denaturing SDS-Page gels. The samples were then subjected to electrophoresis
using a Bio-Rad Mini Protein 3 Western blotting apparatus under 125V of electricity for 1.5
hours to separate the proteins according to size. Bio-Rad Kaleidoscope molecular weight (MW)
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standards were also included on the gels to confirm the molecular weight of the proteins of
interest. Following electrophoresis, protein was transferred from the gels onto a nitrocellulose
membrane (Bio-Rad) using a mini trans-blot apparatus (Bio-Rad) in a Tris-Glycine (Bio-Rad
Cube Solutions) containing 20% methanol under 75V of electricity for 1 hour. To ensure proper
saturation/transfer and that relatively equal volumes of protein were loaded on the gels, the
membranes were stained using Ponceau S.

To identify changes in the level of phosphorylation state of the proteins of interest, the
blots were first blocked with 5% BSA in TBS-T for 1 hour at room temperature with rocking.
Following blocking the membranes were incubated in a solution containing 5% BSA in TBS-T
along with an antibody directed against the protein of interest for one hour at room temperature
(ERK1/2, CaMKII) or overnight at 4 degrees Celcius (pERK1/2, pCaMKII). Following
incubation in the primary antibody solution, the blots were washed in TBS-T three times for 15
minutes each and once in TBS for 5 minutes. Lastly, a solution containing 5% dried non-fat milk
in TBS-T and a secondary antibody (HRP-conjugated goat-anti-rabbit antibody; see table) was
applied to the blots and left to incubate for 1 hour at room temperature. The proteins of interest
(ERK1/2, pERK1/2, CaMKIIα, pCaMKIIα; see Table 1) along with the loading control (alphatubulin) were detected using chemiluminescence (Super-Signal; THERMO Scientific) and
Kodak X-OMAT LS film. Densitometry measurements were obtained using Kodak digital
analysis software and the data analyzed using Microsoft Excel.
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Table 1
Name
alpha-tubulin
ERK1/2
pERK1/2
CaMKIIα
pCaMKIIα
HRP-conjugated
goat

Source
Sigma
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling

Species
rabbit
rabbit
rabbit
rabbit
rabbit

Thermo

rabbit

Dilution Catalogue #
1/50,000 SAB3500023
1/10,000
9102
1/2000
4370
1/2000
3357
1/5000
3361
1/20,000

31210
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2.5

Statistical Analysis
All behavioral data were tested individually for statistical normality and analyzed using

standard two-way repeated-measures ANOVA. Fisher's LSD post-hoc analyses were then
performed to examine group differences for statistical significance within or across levels of
analysis. All protein density data were analyzed by standard T-test. In graphical representations
of the data the vertical bars on the graphs represent group means with error bars representing the
standard error of the mean (SEM). One asterisk ( )٭indicates a difference between two groups
that is statistically significant at p < 0.05. Two asterisks ( )٭٭indicate a level of significance of p
< 0.01.

3.

Results

3.1

Effects of inhibition of intracellular signaling kinases within the BLA on the

acquisition of associative opiate reward learning in previously opiate-naïve animals
To explore the role of the intracellular signaling kinases, MEK and CaMKII, in the
encoding of associative opiate-related reward learning, previously opiate-naïve animals received
bilateral intra-BLA micro-infusions of the potent non-competitive MEK inhibitor UO-126 (0.11.0 μg/0.5 μl) or CaMKII inhibitor KN-62 (.05-1.0 μg/0.5 μl) followed by a systemic injection of
a previously established supra-threshold dose of morphine (5 mg/kg; i.p.) (Bishop et al., 2011;
Lintas et al., 2011; Lintas et al., 2012) or a systemic injection of physiological saline prior to
placement in one of two conditioning environments. A representative microphotograph of
bilateral intra-BLA micro-injector tip placements is shown in Figure 3A. Figure 3B and C show
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a schematic representation of bilateral intra-BLA injector tip placements for four representative
experimental groups.
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Figure Caption 3
Depiction of intra-BLA Guide Cannulae Placement
(A) Micro-photograph of a representative bilateral intra-BLA guide cannulae and injector tip
placement. (B) Schematic representation of bilateral intra-BLA injector tip placements.
previously opiate-naïve animals receiving intra-BLA UO-126 (1.0 μg/0.5 μl).

=

= previously

opiate-naïve animals receiving intra-BLA KN-62 (1.0 μg/0.5 μl). (C) Schematic representation
of bilateral intra-BLA injector tip placements.
receiving intra-BLA KN-62 (1.0 μg/0.5 μl).
intra-BLA UO-126 (1.0 μg/0.5 μl).

= opiate-dependent/withdrawn animals
= opiate-dependent/withdrawn animals receiving
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The results of the place conditioning experiments revealed that bilateral micro-infusions
of the MEK inhibitor (UO-126), but not the CaMKII inhibitor (KN-62), dose-dependently (1.0
μg/0.5 μl) blocked the encoding of opiate-reward learning in previously opiate-naïve animals. At
the high dose of the MEK inhibitor (1.0 μg/0.5 μl) previously opiate-naïve animals failed to
display a significant morphine-related CPP while control animals receiving intra-BLA saline,
low dose UO-126 (0.1 μg/0.5 μl), and all doses of KN-62 (.05-1.0 μg/0.5 μl) displayed a
significant morphine CPP.

The omnibus two-way repeated-measures ANOVA revealed a significant main effect of
group (intra-BLA saline, 0.1 μg, 1.0 μg UO126) (F(2, 45) = 5.6, p<.01), a main effect of treatment
(saline vs. morphine) (F(1, 45) = 188.8, p<.0001), and a significant group (intra-BLA saline, 0.1
μg, 1.0 μg UO-126) X treatment (saline vs. morphine) interaction on times spent in the saline
versus morphine-paired environments (F(2, 45) =29.8, p<0.0001) for animals receiving intra-BLA
UO-126. Fisher’s LSD post hoc analyses were conducted to examine the interaction further. The
post hoc analyses revealed that animals treated with intra-BLA UO-126 at the high concentration
(1.0 μg) spent an equal amount of time in both the morphine and saline-paired environments
(p>.05) whereas intra-BLA UO-126 at the low concentration (0.1 μg) and control animals treated
with intra-BLA saline spent significantly more time in the morphine than saline-paired
environment (p’s<.01) (Figure 4A). Comparing only times spent in the morphine-paired
environments, a significant difference between groups on the time spent in the morphine-paired
side was revealed. Animals in the intra-BLA saline group and the low dose UO-126 group spent
significantly more time in the morphine-paired side than those in the high dose UO-126 group
(p’s<.01).
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Figure Caption 4
Effects of intra-BLA kinase inhibition on opiate reward conditioning in previously opiate-naïve
animals.
(A) In previously opiate-naïve animals, a well established supra-threshold dose of morphine (5
mg/kg; i.p.) produces a robust morphine CPP in control animals receiving intra-BLA saline as
well as in those receiving the low dose of UO-126 (0.1 μg/0.5 μl). However, animals receiving
the high dose of UO-126 (1.0 μg/0.5 μl) fail to display a significant difference in time spent in
either the morphine or saline-paired environment.
(B) In previously opiate-naive animals a supra-threshold dose of morphine (5 mg/kg; i.p.)
produces a robust morphine CPP in animals receiving all doses (.05 μg, 0.5 μg, 1.0 μg/0.5 μl) of
intra-BLA KN-62. Therefore, in previously opiate-naïve animals the high dose of KN-62 fails to
block the acquisition of morphine CPP.
Note: error bars represent standard error (SE); ** denotes significance of p<.01; * denotes
significance of p<.05
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To explore the effect of CaMKII inhibition on the encoding of associative opiate-related
memory, bilateral intra-BLA micro-infusions of KN-62 (.05-1.0 μg/0.5 μl) were administered in
animals in a previously opiate-naive state. At all dose levels (.05-1.0 μg/0.5 μl) intra-BLA
injections of the CaMKII inhibitor, KN-62, failed to block the acquisition of morphine CPP in
previously opiate-naive animals.

The two-way repeated-measures ANOVA revealed a significant main effect of treatment
(saline vs. morphine) (F(1,43) = 216.3, p<.0001) and a group (intra-BLA .05 µg, 0.5 μg, 1.0 μg
KN62) X treatment (saline vs. morphine) interaction on times spent in the morphine versus
saline-paired environments (F(2,43) = 6.0, p=.009) in animals receiving intra-BLA KN-62. Post
hoc analyses revealed that animals treated with intra-BLA KN-62 spent significantly more time
in the morphine than saline-paired environment at all doses of KN-62 (.05-1.0 μg/0.5 μl) (p’s
<.01) (Figure 4B). These experiments indicate that pharmacological inhibition of MEK
phosphorylation, but not CaMKII phosphorylation, within the BLA dose-dependently blocks the
acquisition of associative opiate reward memory in animals in a previously opiate-naïve state.

3.2

Effect of Inhibition of intracellular signaling kinases within the BLA on the

acquisition of associative opiate-related reward learning in opiate-dependent/withdrawn
animals
To explore the role of the intracellular signaling kinases, CaMKII and MEK, in the
encoding of associative opiate-reward learning, opiate-dependent/withdrawn animals received
bilateral intra-BLA micro-infusions of the CaMKII inhibitor KN-62 (0.5-1.0 μg/0.5 μl) or the
MEK inhibitor UO-126 (1.0 μg/0.5 μl) immediately prior to conditioning. The results of the

39
place conditioning experiments revealed that bilateral intra-BLA micro-infusions of the CaMKII
inhibitor, but not the MEK inhibitor, dose-dependently (1.0 μg/0.5 μl) block the encoding of
opiate-reward learning in opiate-dependent/withdrawn animals. At the high dose of the CaMKII
inhibitor (1.0 μg/0.5 μl) animals did not display a significant morphine-related CPP. Control
groups receiving intra-BLA saline, low dose KN62 (0.5 μg/0.5 μl), and high dose UO-126 (1.0
μg/0.5 μl) did display a significant morphine CPP.

The two-way repeated-measures ANOVA revealed a significant main effect of treatment
(saline vs. morphine) (F(1,39) = 108.0, p<.0001) and a significant group (intra-BLA saline, 0.5 μg,
1.0 μg KN-62) X treatment (saline vs. morphine) interaction on times spent in the saline versus
morphine-paired environments (F(2, 39) =40.4, p<.0001) in animals receiving intra-BLA KN-62.
Post hoc analyses revealed that animals treated with KN-62 at the high dose (1.0 μg) spent equal
amounts of time in morphine and saline-paired environments (p>.05) whereas control animals
treated with intra-BLA saline and intra-BLA KN-62 at the low dose (0.5 μg) spent significantly
more time in the morphine than saline-paired environment (p’s<.01) (Figure 5A). Comparing
only times spent in the morphine-paired environments, a significant difference between groups
on the time spent in the morphine-paired side was uncovered. Animals in the intra-BLA saline
group and the low dose KN-62 group spent significantly more time in the morphine-paired side
than those in the high dose KN-62 group (p’s<.01).
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Figure Caption 5
Effect of intra-BLA kinase inhibition on opiate reward conditioning in opiatedependent/withdrawn animals.
(A) In opiate-dependent/withdrawn animals a well established supra-threshold dose of morphine
(5 mg/kg; i.p.) produces a robust morphine CPP in control animals receiving intra-BLA saline as
well as in those receiving the low dose of KN-62 (0.5 μg/0.5 μl). However, animals receiving the
high dose of KN-62 (1.0 μg/0.5 μl) fail to display a significant difference in time spent in either
the morphine or saline-paired environment.
(B) In opiate-dependent/withdrawn animals a supra-threshold dose of morphine (5 mg/kg; i.p.)
produces a robust morphine CPP in control animals receiving intra-BLA saline as well as in
those receiving the effective high dose of UO-126 (1.0 μg/0.5 μl) in previously opiate-naïve
animals. Therefore, in opiate-dependent/withdrawn animals the high dose of UO-126 fails to
block the acquisition of morphine CPP.
Note: error bars represent standard error (SE); ** denotes significance of p<.01; * denotes
significance of p<.05
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To explore the effect of MEK inhibition on the encoding of associative opiate-related
memory bilateral intra-BLA micro-infusions of UO-126 (1.0 μg/0.5 μl) were administered in
animals in an opiate-dependent/withdrawn state. The results revealed no effect of MEK
inhibition on the acquisition of opiate-related memory. The previously established effective dose
of UO-126 (1.0 μg/0.5 μl) in previously opiate-naïve animals failed to block the acquisition of
morphine CPP in opiate-dependent/withdrawn animals (Figure 5B).

The ANOVA revealed a significant main effect of treatment (saline vs. morphine) (F(1,23)
= 191.3, p<.0001) and a group (intra-BLA saline, 1.0 μg UO-126) X treatment (saline vs.
morphine) interaction on times spent in the morphine versus saline-paired environments (F(1,23) =
6.5, p=.028) in animals receiving intra-BLA UO-126. Post hoc analyses revealed that animals
treated with intra-BLA saline and high dose UO-126 (1.0 μg/0.5 μl) spent significantly more
time in the morphine than saline-paired environment (p’s <.01) (Figure 5B). Taken together
these experiments indicate an opiate exposure state-dependent effect of pharmacological
inhibition of CaMKII activation within the BLA. Where inhibition of CaMKII does-dependently
blocks the acquisition of associative opiate reward memory in opiate-dependent and withdrawn
animals, inhibition of MEK fails to block the acquisition of opiate-related learning and memory
in opiate-dependent/withdrawn animals.

3.3

Effects of Intra-BLA intracellular kinase inhibition on intra-VTA morphine reward

acquisition
We administered a dose of morphine previously shown to produce a robust morphine
CPP when micro-infused directly into the VTA (Laviolette & van der Kooy, 2004; Lintas et al.,
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2012; Nader & van der Kooy, 1997) to investigate the effects of kinase inhibition on the
acquisition of associative reward learning via morphine reward cues directly from the VTA.
Figure 6A shows a representative microphotograph of bilateral intra-VTA micro-injector tips.
Figure 6B shows a schematic representation of the bilateral intra-VTA micro-injector tip
placements of two experimental groups described in this section.

44
Figure Caption 6
(A) Microphotograph of a representative bilateral intra-VTA guide cannula and injector tip
placement. (B) Schematic representation of bilateral intra-VTA injector tip placements.
previously opiate-naïve animals receiving intra-VTA morphine (0.5 μg/0.5 μl).
dependent/withdrawn animals receiving intra-VTA morphine (0.5 μg/0.5 μl).

=
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The same dissociation between MEK inhibition and CaMKII inhibition in previouslyopiate-naïve versus opiate-dependent/withdrawn animals observed during systemic
administration of morphine was also observed during intra-VTA morphine administration. At the
established effective dose of UO-126 (1.0 μg/0.5 μl) in previously opiate-naïve animals, the
supra-threshold dose of intra-VTA morphine (0.5 μg/0.5 μl) failed to produce a significant
morphine CPP. However, this same dose of UO-126 when administered in opiatedependent/withdrawn animals did result in a significant morphine CPP. Further, in opiatedependent/withdrawn animals the effective dose of KN-62 (1.0 μg/0.5 μl) for the blockade of
morphine CPP in opiate-dependent/withdrawn via systemic morphine injection also blocked
morphine CPP via intra-VTA morphine micro-injection. Conversely, this dose of KN-62 was
unable to block morphine CPP in previously opiate-naïve animals.

An ANOVA was conducted to examine the effect of intra-BLA MEK inhibition on the
acquisition of morphine-related reward memory via direct intra-VTA micro-infusion of a suprathreshold dose of morphine (0.5 μg/0.5 μl). This analysis revealed a significant main effect of
treatment (saline vs. morphine) (F(1,27) = 12.6, p<.01) and a significant group (previously-opiate
naïve vs. opiate-dependent/withdrawn) X treatment (saline vs. morphine) interaction on time
spent in the morphine versus the saline-paired environment (F(1,27) = 21.4, p<.01). Further post
hoc exploration of the interaction revealed no significant difference between the times spent in
the morphine versus saline-paired environment in previously opiate-naïve animals (p>.05).
However, animals in an opiate-dependent/withdrawn state spent significantly more time in the
morphine-piared than in the saline-paired environment (p<.01) (Figure 7A). When comparing the
times spent in the morphine-paired environment between groups, post hoc analysis revealed a
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significant difference between groups on the time spent in the morphine-paired environment; the
opiate-dependent/withdrawn animals spent more time in the morphine-paired environment than
the previously-opiate naïve animals (p<.05).
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Figure Caption 7
Effect of intra-BLA kinase inhibition on opiate reward conditioning via direct intra-VTA
morphine administration.
(A) In previously opiate-naive animals a well established supra-threshold dose of intra-VTA
morphine (0.5 μg/0.5 μl) fails to produce a morphine CPP in animals receiving the effective high
dose (1.0 μg/0.5 μl) of intra-BLA UO-126. However, opiate-dependent/withdrawn animals
receiving the high dose of UO-126 (1.0 μg/0.5 μl) do spend significantly more time in the
morphine than the saline-paired environment.
(B) In previously opiate-naive animals a well established supra-threshold dose of intra-VTA
morphine (0.5 μg/0.5 μl) produces a robust morphine CPP in animals receiving the effective high
dose of intra-BLA KN-62 (1.0 μg/0.5 μl). However, opiate-dependent/withdrawn animals
receiving the high dose of KN-62 (1.0 μg/0.5 μl) fail to produce significant morphine CPP such
that they spend an equal amount of time in both the morphine and saline-paired environments.
Note: error bars represent standard error (SE); ** denotes significance of p<.01; * denotes
significance of p<.05
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The analysis conducted to examine the effect of CaMKII inhibition on the encoding of
opiate-reward via intra-VTA morphine revealed a significant main effect of group (previously
opiate-naïve vs. opiate-dependent/withdrawn) (F(1,27) = 10.9, p<.01), a significant main effect of
treatment (saline vs. morphine) (F(1,27) = 32.6, p<.01), and a significant group (previously opiatenaïve vs. opiate-dependent/withdrawn) X treatment (saline vs. morphine) interaction (F(1,27) =
24.9, p<.01) on times in the morphine or saline-paired environment. Post hoc analysis showed
that previously opiate-naïve animals spent significantly more time in the morphine rather than
the saline-paired environment (p<.01) while opiate-dependent/withdrawn animals did not differ
in their time spent in either environment (p>.05) (Figure 7B). In comparing the two groups total
time spent in the morphine-paired environment, post hoc analysis revealed a significant
difference between groups in their times spent in the morphine-paired environment such that
previously opiate-naïve animals spent significantly more time in the morphine-paired
environment than the opiate-dependent animals (p<.01).

These results closely mirror the opiate exposure state-dependent dissociation between
MEK and CaMKII inhibition on the acquisition of morphine-reward memory when morphine
was delivered systemically. The results suggest a state-dependent switch within the
mesocorticolimbic system from an opiate-naïve MEK dependent pathway to an opiatedependent/withdrawn CaMKII dependent pathway in the formation of opiate-related associative
memories.
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3.4

Examining the permanency of the functional switch from previously opiate-naive

MEK to opiate-dependent/withdrawn CaMKII pathways in the encoding of associative
opiate-related memory.
Next, the longevity of the functional switch from a MEK-dependent pathway to a
CaMKII-dependent pathway in the acquisition of opiate-reward related associative memories
was examined. The animals were exposed to the standard seven day schedule of heroin injections
followed by a seven day recovery period to ensure animals were in a drug free state on the first
day of CPP conditioning. The results of these experiments indicated that the functional switch
from pMEK-dependent encoding of associative memory to pCaMKII-dependent encoding of
associative memory is long lasting. The group of opiate-recovered animals receiving intra-BLA
MEK inhibitor (1.0 µg/0.5 µl) displayed a significant morphine-CPP while animals receiving
intra-BLA CaMKII inhibitor (1.0 µg/0.5 µl) failed to display a significant morphine-CPP.

The statistical analysis conducted to examine the effect of intra-BLA MEK inhibition
revealed a significant main effect of treatment (saline vs. morphine) (F(1,43) = 114.1, p<.0001)
and a significant group (previously opiate-naive, opiate-dependent/withdrawn, opiate-recovered)
X treatment (saline vs. morphine) interaction for times spent in the morphine versus saline-paired
environments (F(2,43) = 13.8, p<.001). Post hoc analyses revealed no significant difference
between times spent in the morphine or saline paired side for animals in a previously opiatenaive state (p>.05). However, animals in an opiate-dependent/withdrawn and opiate-recovered
state spent significantly more time in the morphine- than the saline-paired environment (p's<.01).
Furthermore, when comparing the total times spent in the morphine-paired environments
between groups the opiate-dependent/withdrawn and opiate-recovered groups spent significantly
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more time in the morphine-paired environment than the previously opiate-naive group (p's<.01)
(Figure 8A).
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Figure Caption 8
Plasticity of intra-BLA kinase inhibition on opiate reward conditioning.
(A) In previously opiate-naive animals receiving the effective high dose (1.0 μg/0.5 μl) of intraBLA UO-126, a supra-threshold dose of morphine (5 mg/kg; i.p.) fails to produce morphine
CPP. However, opiate-dependent/withdrawn and opiate-recovered animals receiving the high
dose of UO-126 (1.0 μg/0.5 μl) versus the supra-threshold dose of morphine (5 mg/kg; i.p.) did
spend significantly more time in the morphine than the saline-paired environment.
(B) In previously opiate-naive animals receiving the effective dose (1.0 μg/0.5 μl ) of intra-BLA
KN-62 a supra-threshold dose of morphine (5 mg/kg; i.p.) produced a robust morphine CPP.
However, opiate-dependent/withdrawn and opiate-recovered animals receiving the high dose of
KN-62 (1.0 μg/0.5 μl) failed to display a significant morphine CPP such that they spend an equal
amount of time in both the morphine and saline-paired environments.
Note: error bars represent standard error (SE); ** denotes significance of p<.01; * denotes
significance of p<.05
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The ANOVA conducted to examine the effect of intra-BLA CaMKII inhibition revealed
a main effect of treatment (saline vs. morphine) (F(1,41) = 47.6, p<.0001) and a significant group
(previously opiate-naive, opiate-dependent/withdrawn, opiate-recovered) X treatment (saline vs.
morphine) interaction on times spent in the morphine- versus saline-paired environments (F(2,41)
= 48.5, p<.001). Post hoc analyses revealed that animals in a previously opiate-naive state spent
significantly more time in the morphine- than the saline-paired environment (p<.01). Those in
the opiate-dependent/withdrawn and opiate-recovered groups however spent an equal amount of
time in both the morphine- and the saline-paired environments (p's>.05). Comparing the times
spent between groups in the morphine-paired environment the previously opiate-naive group
spent significantly more time in the morphine-paired environment than both the opiatedependent/withdrawn and opiate-recovered groups (p's<.01) (Figure 8B).

These results clearly indicate that the functional switch from a MEK dependent pathway
in previously opiate-naive animals to a CaMKII dependent pathway in opiatedependent/withdrawn animals is a long lasting one. Opiate-recovered animals receiving intraBLA MEK inhibitor displayed a strong morphine CPP while those receiving intra-BLA CaMKII
inhibitor failed to display morphine CPP.

3.5

Pharmacological inhibition of intracellular signaling kinases blocks the DA receptor

mediated potentiation of morphine CPP to a sub-threshold dose of morphine
Previous research has demonstrated that intra-BLA agonism of DA D1-like and D2-like
receptors in previously opiate-naive and opiate-dependent/withdrawn animals, respectively, can
potentiate morphine CPP to a sub-threshold dose of morphine (Lintas et al., 2011; Lintas et al.,
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2012). Normally a sub-threshold dose (.05 mg/kg; i.p.) of morphine fails to produce a significant
morphine CPP (Bishop et al., 2011; Lintas et al., 2011; Lintas et al., 2012) however, in
previously opiate-naive animals receiving an intra-BLA DA D1-like receptor agonist the subthreshold dose of morphine successfully produces a morphine CPP. Similarly, in opiatedependent/withdrawn animals receiving an intra-BLA DA D2-like receptor agonist this same
sub-threshold dose of morphine successfully produces morphine CPP. Given the functional link
between DA D1-like receptors and MEK activation (Fricks-Gleason & Marshall, 2011;
O'Sullivan et al., 2008; Pan et al., 2011) we hypothesized that pharmacological agonism of intraBLA D1-like receptors coupled with MEK inhibition would result in a blockade of the
previously established potentiation of a sub-threshold dose of morphine in previously opiatenaive animals. Further, based on previous research suggesting a link between DA D2-like
receptors and CaMKII activation (Gu, Jiang, Yuen, & Yan, 2006; Gu & Yan, 2004; Liu et al.,
2009), it was hypothesized that pharmacological agonism of intra-BLA D2-like receptors
coupled with CaMKII inhibition would block the potentiation of a sub-threshold dose of
morphine in opiate-dependent/withdrawn animals. To explore this idea we first replicated the
D1R and D2R mediated potentiation of morphine CPP in previously opiate-naive and opiatedependent/withdrawn animals, respectively. Subsequently, we co-administered a D1R agonist
(SKF-81297) with the MEK inhibitor (UO-126) into the BLA of animals in a previously opiatenaive state and co-administered a D2R agonist (Quinpirole) with the CaMKII inhibitor (KN-62)
into the BLA of opiate-dependent/withdrawn animals during the conditioning phase against a
sub-threshold dose of morphine (.05 mg/kg; i.p.).

57
The results of these experiments revealed a significant morphine CPP in previously
opiate-naive animals receiving sub-threshold morphine and intra-BLA saline or SKF-81297 (1.0
µg/0.5 µl) and a blockade of morphine CPP in animals receiving sub-threshold morphine with
intra-BLA co-administration of SKF-81297 and UO-126 (1.0 µg/0.5 µl). Further, opiatedependent/withdrawn animals receiving sub-threshold morphine and intra-BLA saline or
Quinpirole (1.0 µg/0.5 µl) displayed a significant morphine CPP while those receiving intraBLA co-administration of Quinpirole and KN-62 (1.0 µg/0.5 µl) did not show a significant
morphine CPP.

The results from the analysis conducted to examine the effect of intra-BLA D1R agonism
as well as D1R agonism coupled with MEK inhibition against a sub-threshold dose of morphine
(.05 mg/kg; i.p.) revealed a significant group (Saline, SKF-81297, SKF-81297+UO-126) X
treatment (saline vs. morphine) interaction on times spent in the morphine versus the saline
paired environments (F(2,45) = 19.3, p<.0001). Post hoc analyses revealed that those in the SKF81297 group spent significantly more time in the morphine- than the saline-paired environment
(p<.01). However, the saline and the SKF-81297+UO-126 groups spent an equal amount of time
in both the morphine- and saline-paired environments (p>.05). In addition, when comparing
times spent in the morphine-paired environment between groups, the SKF-81297 group spent
significantly more time in the morphine-paired environment than the saline and SKF81297+UO-126 groups (p<.01) (Figure 9A).
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Figure Caption 9
Blockade of DA receptor mediated potentiation of sub-threshold morphine CPP by intracellular
signaling kinase inhibition.
(A) In previously opiate-naive animals receiving intra-BLA SKF-81297 (1.0 μg/0.5 μl), a subthreshold dose of morphine (.05 mg/kg; i.p.) produces a significant morphine CPP. However, in
animals receiving intra-BLA saline or SKF-81297+UO-126 (1.0 μg/0.5 μl), a sub-threshold dose
of morphine (.05 mg/kg; i.p) failed to produce a significant morphine CPP.
Note: Intra-BLA saline data courtesy of Bishop et. al., (2011)
(B) In opiate-dependent/withdrawn animals receiving intra-BLA Quinpirole (1.0 μg/0.5 μl), a
sub-threshold dose of morphine (.05 mg/kg; i.p.) produced a significant morphine CPP.
However, in animals receiving intra-BLA saline or Quinpirole+KN-62 (1.0 μg/0.5 μl), a subthreshold dose of morphine (.05 mg/kg; i.p.) failed to produce a significant morphine CPP.
Note: Intra-BLA saline data courtesy of Lintas et. al., (2012); ** denotes significance of p<.01; *
denotes significance of p<.05
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The two-way ANOVA conducted to examine the effect of intra-BLA D2R agonism as
well as D2R agonism coupled with CaMKII inhibition against a sub-threshold dose of morphine
(.05 mg/kg; i.p.) revealed a significant group (Saline, Quinpirole, Quinpirole+KN-62) X
treatment (saline vs. morphine) interaction on times spent in the morphine versus the saline
paired environments (F(2,45) = 5.92, p<.01). Post hoc analyses revealed that those in the
Quinpirole group spent significantly more time in the morphine- than the saline-paired
environment (p<.01). However, the saline and Quinpirole+KN-62 groups spent an equal amount
of time in both the morphine- and saline-paired environments (p>.05). In addition, when
comparing times spent in the morphine-paired environment between groups, the Quinpirole
group spent significantly more time in the morphine-paired environment than the
Quinpirole+KN62 group (p<.05) (Figure 9B).

3.6

Opiate-exposure state modulates the density of signaling kinase protein expression
There is an extensive literature which suggests that acute and chronic exposure to drugs

as well as abstinence or withdrawal from drugs cause significant changes in the levels of
pMEK(ERK1/2) and pCaMKII expressed within the MCLS. To explore this phenomenon in the
BLA, we exposed one group of animals to 15 days of saline injections (s.c.) and one group to 15
days of heroin injections (0.5 mg/kg; s.c.). The heroin and saline injections were carried out for
15 days in order to mimic the number of injections our previous DWD groups received during
the formation of dependence and subsequent conditioning phase. Twenty-one hours following
their last injection the animals were sacrificed and a section of their BLA removed for analysis.
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Western Blot analyses of the density of protein expression of total ERK1 (ERK1) and
pERK1 in PN animals versus DWD animals revealed no change in ERK expression between
groups (PN, DWD) (p>.05) but a significant difference in the expression of pERK1 in DWD
animals compared to the PN animals. The difference was such that DWD group displayed a
significant decrease in pERK1 expression compared to the PN group (t(12) = 3.75, p<.01).
Similarly, the analysis of ERK2 and pERK2 revealed no change in ERK2 expression between
groups (PN, DWD) (p>.05) but a significant difference in pERK2 expression between PN and
DWD groups. Again, there was a significant decrease in the expression of pERK2 in DWD
animals compared to the PN animals (t(12) = 3.11, p<.05). (Figure 10).
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Figure Caption 10
Withdrawal from chronic opiate-exposure modulates the expression of phosphorylated ERK1/2
within the BLA.
(A) Graph of the expression of total ERK1 and 2 (ERK1/2) and picture of protein blots in PN
and DWD groups of α-tubulin control, ERK1, and ERK2. Within the BLA ERK1 and 2
expression is unchanged between animals in an opiate-naive (PN) and opiatedependent/withdrawn (DWD) state.
(B) Graph of the expression of phosphorylated ERK1 and 2 (pERK1/2) and picture of protein
blots in opiate-naive (PN) and opiate-dependent/withdrawn animals (DWD) groups of α-tubulin
control, pERK1, and pERK2. The expression of the phosphorylated form of ERK1 and 2
(pERK1/2) within the BLA is significantly decreased in DWD in comparison to animals in a PN
state.
(C) Graph of the ratio of the pERK1/2 to the total ERK1/2 expressed in the opiate-naive (PN)
group compared to the opiate-dependent/withdrawn (DWD) group. The ratio of pERK1/2 to
ERK1/2 expressed in the DWD group is significantly less than that of the PN group
Note: error bars represent standard error (SE); ** denotes significance of p<.01; * denotes
significance of p<.05
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Preliminary analyses of the density of protein expression of total CaMKIIα (CaMKIIα)
and phosphorylated CaMKIIα (pCaMKIIα) in PN animals versus DWD animals revealed a large
difference in CaMKIIα levels and pCaMKIIα expression between groups (PN, DWD). There was
a dramatic decrease in total CaMKIIα levels and pCaMKIIα expressions in the DWD group
compared to the PN group (Figure 11). *The data for the quantification of CaMKIIα and
pCAMKIIα protein density are still being analyzed. However, preliminary examination of the
Western Blots indicates a chronic opiate exposure-mediated decrease in total and phosphorylated
CaMKII.
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Figure Caption 11
Withdrawal from chronic opiate-exposure modulates total CaMKII and phosphorylated
CaMKIIα within the BLA.
(A) Photograph of protein blots in PN and DWD groups of α-tubulin control, CaMKIIα, and
pCaMKIIα. Within the BLA CaMKIIα and pCaMKIIα expression is dramatically decreased
between animals in an opiate-naive (PN) and opiate-dependent/withdrawn (DWD) state.
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4.

Discussion
We previously reported a functional switch within the BLA between DA D1- and D2-like

receptor transmission in the formation of opiate-related associative memories as a function of
opiate-exposure state (Lintas et al., 2011). However, the underlying intracellular molecular
mechanism(s) responsible for this switch was unclear. It was hypothesized that modulation of
intracellular MEK phosphorylation, a molecule important in altering plasticity in cellular
structure and function, may be partly responsible for the D1-mediated formation of associative
memories in previously opiate-naive animals. Further, it was hypothesized that modulation of
intracellular CaMKII phosphorylation, also important in controlling neuronal plasticity, might
serve as an underlying mechanism for D2R-mediated modulation of opiate-related associative
memory formation, in the opiate-dependent/withdrawn state. The present results strongly
implicate both MEK and CaMKII as critical molecular substrates sub-serving the functional
effects of intra-BLA D1/D2 transmission during the formation of associative opiate reward
memory. In addition, the results demonstrate a novel molecular alteration between
phosphorylation of MEK and CaMKII levels as a functional consequence of chronic opiate
exposure.

4.1

Overview of Behavioral Results
Using an unbiased CPP behavioral paradigm, a novel molecular-memory switch within

the BLA was identified. Specifically, the results show that the formation of opiate-related
associative memories in the BLA depends upon the phosphorylation of MEK (pMEK) in
previously opiate-naive animals but switches to a phosphorylated CaMKII (pCaMKII)dependent mechanism in opiate-dependent/withdrawn animals. The results demonstrate that in
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previously opiate-naive animals, intra-BLA administration of a pharmacological inhibitor of
MEK phosphorylation before conditioning impaired the animals' ability to encode a morphinerelated conditioned associative memory. However, the same pMEK inhibitor administered to
opiate dependent and withdrawn animals had no influence on the encoding of morphine-related
associative memory. In opiate dependent and withdrawn animals, intra-BLA administration of a
pharmacological inhibitor of CaMKII phosphorylation before conditioning blocked the encoding
of a morphine-related conditioned associative memory. However, intra-BLA inhibition of
CaMKII signaling was entirely ineffective in modulating opiate reward memory formation in
previously opiate-naïve animals.

The VTA is not the only structure within the MCLS that contains µ-opiate receptors.
Indeed, opiate-class drugs act on opiate receptor subtypes beyond the µ subtype, that trigger
neurotransmission within other neural pathways extrinsic to the MCLS (Ford et al., 2006;
Olmstead & Franklin, 1997). To bypass structures other than the VTA, such as the NAc,
containing µ-opiate receptors, and focus on the DAergic pathway between the VTA and BLA
specifically, morphine was administered directly into the VTA. The results obtained from intraVTA morphine administration mirrored those found when morphine was administered
systemically. Thus, the results demonstrate that the molecular-switch does rely upon the
activation of DAergic projections from the VTA specifically. More importantly, these findings
implicate the BLA as a critical modulator of opiate-related motivational information arising
directly from the VTA.
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It is important to identify long lasting changes in neuronal structure and function taking
place following chronic drug use. This is especially essential given that there is such a high risk
for opiate abuse relapse, even following years of successful abstinence. The molecular switch
observed in the current investigation appears to be a long lasting change such that inhibition of
pCaMKII, but not pMEK, continued to block the formation of associative memories even when
animals were in an opiate-recovered state, following chronic exposure. This evidence suggests a
long-lasting molecular change occurring in response to chronic drug exposure. This is a very
important observation when considering possible implications for novel treatment models for
opiate addiction. A common focus of research in the field of opiate addiction is to identify long
lasting neurobiological and/or behavioral changes which occur following chronic drug exposure
because they may speak to the long lasting susceptibility for relapse following abstinence in
people suffering from drug addictions. While future studies are required to address these issues,
our findings identify a novel molecular switch specifically within the BLA, which may
ultimately underlie the longer term effects of chronic opiate exposure, dependence, and relapse.

Finally, MEK and CaMKII are ubiquitous signaling molecules, expressed within many
neuronal sub-types in multiple neural regions. In addition, both molecules are modulated by
many extra- as well as intra-cellular events (Fink & Meyer, 2002; Seger & Krebs, 1995). For
this reason, the functional relationship between the activation of D1R and D2R's and the
subsequent phosphorylation of MEK and CaMKII, respectively, was examined. Intra-BLA
administration of a D1R-agonist prior to morphine conditioning with a sub-threshold
conditioning dose of morphine potentiates the reward salience of opiates in previously opiatenaive animals but not opiate-dependent and withdrawn animals (Lintas et al., 2012). However,
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administration of a D2R-agonist prior to conditioning potentiates the reward salience of
morphine specifically in opiate-dependent and withdrawn animals but not previously opiatenaive animals (Lintas et al., 2012). In the current investigation, by coupling the D1-agonist with
the MEK inhibitor in previously opiate-naive animals, we were able to block the D1-agonist
mediated potentiation of morphine-conditioned place preference. Similarly, by coupling the D2agonist with the CaMKII inhibitor in opiate-dependent/withdrawn animals, we were able to
block the D2-agonist mediated potentiation of morphine-conditioned place preference. These
findings strongly support our suggestion of a functional relationship between the DA D1-like and
DA D2-like families of receptors and the MEK and CaMKII intracellular signaling cascades,
respectively.

4.2

Overview of Molecular/Protein Expression Experimental Results
A series of Western Blot protein expression analyses were conducted to investigate the

changes in protein expression occurring in response to chronic opiate exposure and withdrawal
within the BLA. In our original hypothesis, we expected to find equal expression of total protein
levels between opiate-naive and opiate-dependent and withdrawn groups and increased levels of
pERK1 and 2 in opiate-naive groups. In addition, based on our behavioural observation of
increased sensitivity to CaMKII inhibition specifically following chronic opiate exposure, our
hypothesis predicted increased levels of pCaMKII in opiate-dependent and withdrawn groups. In
agreement with our expectations regarding MEK signaling, we found expression of total ERK1
and 2 to be equal across groups and phosphorylated ERK1 and 2 levels to be higher in the opiatenaive than the opiate-dependent/withdrawn group. However, interestingly, total CaMKII
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expression as well as pCaMKII levels were dramatically decreased in the opiate-dependent and
withdrawn group compared to the opiate-naive group.

Although unexpected, our findings do follow what similar investigations of CaMKII
expression following chronic administration and withdrawal from addictive substances have
reported. Specifically, pCaMKII levels increase from baseline during chronic drug exposure and
dramatically decrease during abstinence and/or withdrawal from drug exposure (Christian et al.,
2012; Greenstein et al., 2007; Lou et al., 1999; Papaleo et al., 2012; Wang & Wang, 2006; Zhong
et al., 2006). In the current investigation, animals that received 15 days of heroin injections were
in 21 hours of withdrawal when they were sacrificed for protein density analysis. Hence, the
dramatic down-regulation of total CaMKII expression uncovered in the analysis coincides with
research demonstrating a similar down-regulation of CaMKII in animals following chronic
exposure to and withdrawal from addictive substances. However, the current investigation is
unique from those previously reported because it examined protein density specifically within
the amygdala. Past research concerning CaMKII protein expression and pCaMKII levels
following chronic drug exposure and withdrawal examined larger areas such as the PFC or
hippocampus and reported a down-regulation in pCaMKII levels but little or no change in total
CaMKII levels (Lou et al., 1999; Wang & Wang, 2006). The results reported here show a
dramatic decrease in total CaMKII expression within the amygdala of opiate-dependent and
withdrawn animals in comparison to opiate-naive animals. The decrease in pCaMKII levels
logically follows from the dramatic drop in total CaMKII expression. This evidence is intriguing;
it suggests that chronic opiate use and withdrawal does not just affect the phosphorylation state
of CaMKII but total protein levels in and of themselves.
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4.3 Dopamine D1-like Receptors and pMEK
As mentioned previously, activation of D1 receptors within the MCLS is associated with
increased levels of pMEK (Alvarez-Jaimes et al., 2005; Fricks-Gleason & Marshall, 2011; Kelly
et al., 2003; T. Li et al., 2010; Pan et al., 2011). As we have previously reported, D1R activation
in the BLA is necessary for the formation of associative memories in PN animals (Lintas et al.,
2011). Similarly, in the current project intra-BLA pMEK levels were higher in opiate-naive than
in opiate dependent and withdrawn animals and MEK phosphorylation was necessary for the
formation of opiate-related reward memories in previously opiate-naive but not opiate-dependent
and withdrawn animals. The fact that pMEK levels were significantly lower in opiate-dependent
and withdrawn than in opiate-naive animals suggests that D1R activity decreased and MEK
phosphorylation was no longer necessary for the formation of associative memories in opiatedependent and withdrawn animals. Furthermore, the fact that we were unable to disrupt the
formation of associative memories in opiate-dependent and withdrawn animals via
pharmacological blockade of pMEK also supports the notion that MEK phosphorylation is no
longer necessary for the formation of associative memories in an opiate-dependent and
withdrawn state.

4.4

Dopamine D2-like Receptors and pCaMKII
As discussed previously, evidence suggests that the expression of D2 receptors is

decreased (Collins et al., 2011; Volkow et al., 1993) and their binding affinity or activity state
increased (Novak & Seeman, 2010) following chronic drug use and withdrawal. Similarly,
withdrawal from chronic drug administration is also associated with a decrease in pCaMKII
levels (Christian et al., 2012; Frankland et al., 2001; Lisman et al., 2002; Lou et al., 1999; Lu et
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al., 2000; Wanjerkhede & Bapi, 2008). Interestingly, research shows that the expression of
CaMKII within the cell is modulated differentially by D2R's depending on the activity state
D2R's are in at the time. When in a low activity state, D2R activation is associated with an
increase in pCaMKII levels through mobilization of intracellular calcium stores but when in a
high activity state, D2R activation is associated with a decrease in pCaMKII levels (Gu & Yan,
2004). Thus, there are two potential mechanisms implied by the behavioural and protein density
analyses reported here. First, the overall decrease in total CaMKII within the BLA in opiatedependent and withdrawn animals suggests that the total number of D2R's in the BLA decreased.
Second, the decrease in pCaMKII observed in opiate-dependent and withdrawn animals suggests
that those remaining D2R's were in a high affinity, high activity state. The fact that intra-BLA
pharmacological blockade of D2R's (Lintas et al., 2011) and pCaMKII inhibition impair the
formation of associative memories in opiate-dependent and withdrawn but not previously opiatenaive animals, suggests that when in an opiate-dependent/withdrawn state, DA transmission
from the VTA preferentially activates D2R's in their high affinity state and facilitates the
formation of associative memories through a CaMKII-dependent molecular substrate. In
addition, although total intra-BLA CaMKII levels were dramatically reduced in the opiatedependent withdrawn state, CaMKII signaling is required for the formation of opiate-related
associative memory, as blockade of CaMKII signaling specifically in the opiate-dependent and
withdrawn state completely prevents the formation of opiate-related associative memories. In
direct contrast, inhibition of CaMKII signaling in the previously opiate-naïve state has no
influence on opiate-related associative memory acquisition.

4.5

Proposed Model of Opiate Exposure State-Dependent Associative Learning
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The MCLS is a highly malleable circuit, constantly modifying itself in order to maintain
a level of balance and homeostasis between its component parts. The MCLS is able to adapt to
changes on an ongoing basis through the plasticity of individual neurons and through the
plasticity of synaptic connections between groups of neurons. In addition to previous research,
the results presented in the current investigation demonstrate clear and concise evidence of the
ability of the MCLS to adapt to drug-induced changes. For example, in response to chronic
opiate use, an up-regulation in DA transmission followed by a decrease in DA concentration
during withdrawal occurs. The number of DA receptors available on neurons decreases and their
binding affinity modulated such that D2R binding affinity increases. The chronic drug userelated decrease in D1R expression results in decreased pMEK levels as well as decreased D2R
expression coupled with increased D2R binding affinity that leads to decreased total and
pCaMKII levels. These drug-related modifications translate into an observable switch in the
ability of a D1-antagonist or pMEK-inhibitor and D2-antagonist or pCaMKII-inhibitor to effect
the acquisition of opiate-related reward memories based on opiate-exposure state at the time of
encoding. Put another way, when animals are in a previously opiate-naive state the MCLS is
functioning naturally, an increase in DA transmission due to the introduction of morphine into
the system preferentially activates D1R's triggering phosphorylation of MEK in the BLA,
facilitating the formation of associative memories. Following chronic exposure to opiates and
chronic increases in DA concentration within the MCLS, the number of DA receptors decreases.
Once opiate concentrations decrease within the MCLS, the concentration of extracellular DA
drops exponentially, the binding affinity of D2R's increases, and the expression of
phosphorylated CaMKII decreases. Presumably then, once opiates are reintroduced into the
system, DA transmission increases once again and preferentially targets D2R's in their high
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affinity state possibly increasing Ca2+ mobilization and phosphorylation of CaMKII and
facilitating associative memory formation (see Figure 12 for depiction of proposed model).
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Figure Caption 12
Proposed model of the formation of associative memories in previously opiate-naïve versus
opiate-dependent/withdrawn animals.
Scenario A) Blue DA projection. Opiates bind to μ-opiate receptors on GABAergic interneurons
in the VTA releasing GABAergic inhibition over local DA neurons and facilitating DAergic
release to the BLA and NAc. In the opiate-naive state the DAergic projection from the VTA to
the BLA (blue DA projection) preferentially activates D1R’s on GABAergic neurons and
promotes MEK(ERK) phosphorylation. This causes GABAergic inhibition over local pyramidal
neurons to be released. Simultaneously, sensory cortex input to the BLA is facilitated. This series
of events facilitates GLUergic BLA output towards the mPFC and NAc, and subsequently NAc
GLUergic projections to motor cortex.
Scenario B) Red DA projection. Through repeated activation of this system via chronic opiate
exposure GLUergic projections from the mPFC to the BLA are modulated and the number of
D2R’s is increased and the expression of pCaMKII is increased. During opiate withdrawal there
is a decrease in DAergic transmission coupled by an increase in D2R sensitivity and a decrease
in the expression of pCaMKII as well as tCaMKII. Presumably then, the system is primed for
direct inhibition of GLUergic projections from the mPFC towards GABAergic neurons in the
BLA (red DA projection) and facilitating BLA Gluergic projections towards the NAc upon
subsequent administration of opiates.
Note: VTA: ventral tegmental area; BLA: basolateral nucleus of the amygdala; NAc: nucleus
accumbens; mPFC: medial pre-frontal cortex; DA: dopaminergic neuron; GABA: GABAergic
neuron; pMEK: phosphorylated MEK; pCaMKII: phosphorylated CaMKII.

77

pyramidal

PFC
Sensory
Cortex

+

VTA

D2R/
pCaMKII
_

GABA

- DA

+
_

BLApyramidal+
_

GABA
D1/
pMEK
_

+

Nac
Shell

Motor
+ Cortex

Figure 12

78
5. Future Directions
The protein density analyses presented in the investigation presented here revealed
decreased levels of pMEK and decreased total and phosphorylated CaMKII levels suggesting
that DA D1R expression had decreased, D2R expression had decreased, and D2R binding
affinity had increased in opiate-dependent/withdrawn animals. Further studies are required to
confirm the down regulation of DA D1R and D2R expression in the amygdala following chronic
opiate administration and withdrawal.

The investigation of intra-BLA MEK and CaMKII phosphorylation inhibition revealed an
opiate-exposure state-dependent molecular switch in the acquisition of opiate-related associative
memories. However, intra-BLA activation of MEK and CaMKII phosphorylation was not
investigated. It is possible to potentiate the formation of an associative opiate-related memory to
a sub-threshold conditioning dose of morphine by pharmacologically activating D1R and D2R's
in previously opiate-naive and opiate-dependent/withdrawn animals, respectively (Lintas et al.,
2012). It follows logically that intra-BLA activation of pMEK in previously opiate-naive and
pCaMKII in opiate-dependent/withdrawn animals should potentiate the formation of an opiaterelated associative memory to a sub-threshold dose of morphine. If intra-BLA pMEK and
pCaMKII activation revealed a similar opiate-exposure state-dependent molecular-switch in
potentiation of opiate-related associative memories it would add to evidence suggesting a
functional link between D1R's and pMEK, and D2R's and CaMKII. Confirmation of a functional
link between the two families of DA receptors and the two intracellular signaling cascades has
important implications for the development of new treatments for opiate addiction. For example,
pharmacological interventions designed to modulate DA levels to correct neuropsychological
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disorders, are associated with a number of adverse long term side effects. A treatment designed
to target the intracellular protein kinases associated with DA receptor activation rather than DA
levels directly, may be able to bypass the adverse side effects associated with DA agonists or
antagonists.

The molecular switch to a pCaMKII-dependent mechanism for the formation of opiaterelated associative memories observed in the current investigation remained following recovery
from withdrawal. This evidence suggests that opiate exposure-induced changes in CaMKII
expression and CaMKII phosphorylation may represent a stable molecular switch taking place
within the BLA. Further investigation to test the longevity of the molecular-switch to a
pCaMKII-dependent mechanism for reward related memory formation may have important
therapeutic implications. In fact, the goal of most addiction-related research is to elucidate any
permanent neurobiological changes taking place following chronic drug use because such
changes, if reversed, may assist with the treatment of opiate-addiction related craving and relapse
phenomena. Thus, further testing to explore the longevity of the molecular switch to a pCaMKIIdependent pathway in opiate-related memory formation is necessary. If the evidence suggested
the switch to a pCaMKII-dependent pathway in the formation of opiate-related memories was
permanent, an important next step would be to investigate the effect of a treatment designed to
restore CaMKII levels to normal levels in preventing cue-induced relapse.

6.

Conclusions
Taken together the results strongly indicate a novel molecular-memory switch taking

place within the BLA due to chronic opiate exposure and withdrawal. This evidence is an
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important step forward in understanding the long-lasting neuromolecular changes caused by
chronic opiate exposure. In addition, understanding the underlying molecular substrates
responsible for the formation and persistence of opiate-related associative memories will provide
a clearer understanding of opiate-related relapse and craving in human addicts. Further research
is required to elucidate the long-term behavioral significance of the findings. However, the
results have revealed some important molecular targets for future research which may hold
significance in the development of pharmaco-therapeutic treatments for people suffering from
opiate addiction.
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Appendix
Figure 4

A
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

saline
7
83.4
25.9
9.8

0.1µg UO-126
8
92.3
42.2
14.9

1.0µg UO-126
8
203
64.2
22.7

461.7
25.8
9.7
-11.4
<.01

413.9
57.5
20.3
-10.4
<.01

257.3
64.1
22.7
-1.8
>.05

.05µg KN62
7
73.3
40.3
15.2

0.5µg KN-62
7
101
53.4
20.2

450.7
68.9
26
-10.7
<.01

398.9
55
20.8
-8.4
<.01

B

Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

1.0µg KN-62
8
153.8
42.7
11.8
361
32.3
11.4
-6.3
<.01
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Figure 5
A
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

saline
6
86
41.7
15

0.5µg KN-62
7
167.7
41
15.3

5.0µg KN-62
7
250.1
12.5
4.7

447.5
63.5
29.5
-11.8
<.01

340.9
52.6
19.9
-6.1
<.01

240.7
29.2
11
0.33
>.05

B
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

saline
6
86
41.7
17

1.0µg UO-126
6
126.7
18.8
7.7

447.5
63.5
26
-11.9
<.01

375
10.8
4.4
-8
<.01
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Figure 7

A
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

PN
7
246.7
37.1
13.7
229.4
29
10.9
0.76
>.05

DWD
7
165.1
20.2
7.6
295.7
57.7
25.3
-5.8
<.01

Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

PN

DWD

183.6
33.6
12.7
315.4
21.5
8.1
-7.6
<.01

225.9
26.4
10
221.4
29
11
-0.5
>.05

B
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Figure 8

A
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

PN
8
203
64.2
22.7
257.3
64.1
22.7
-2.1
>.05

DWD
6
126.7
18.8
7.7
375
10.8
4.4
-8.2
<.01

RCV
8
150.3
40.1
14.9
361.4
25.8
9.1
-8
<.01

Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

PN
8
153.8
42.7
11.8
361
32.3
11.4
-12.9
<.01

DWD
7
250.1
12.5
4.7
2400.7
29.2
11
0.55
>.05

RCV
6
235.8
26.2
10.8
244.3
10.3
4.2
-0.46
>.05

B
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Figure 9

A

Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

Saline
7
262.7
65.8
24.9
247.8
59.2
20.9
0.5
>.05

SKF
8
144.4
27.4
9.7
366.8
24.4
8.6
-7.9
<.01

SKF+UO126
8
242.9
45.8
16.2
228.4
11.3
4
-1
>.05

Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

Saline
8
257.9
63.7
22.5
269.9
61.3
21.7
-0.42
>.05

Quinpirole
8
187.4
31.9
11.3
313.9
21.3
7.5
-4.4
<.01

Quinpirole
+KN-62
8
241.3
20.6
7.8
237.9
16.2
6.1
0.11
>.05

B
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Figure 10
A
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

tERK1
7
1
0.01
0.005

tERK2
7
1
0.02
0.007

0.89
0.01
0.005
1.73
0.11

0.9
0.17
0.063
0.66
0.52

B
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine
Side
SD Morphine Side
SEM Morphine Side
t-Value
p

pERK1

pERK2

7
7
0.996
1.01
0.14
0.009
0.141762 0.036824
0.358
0.591
0.062
0.114
0.081722 0.127694
3.75
3.11
0.003
0.008

C
Group
Size
Mean Saline Side
SD Saline Side
SEM Saline Side
Mean Morphine Side
SD Morphine Side
SEM Morphine Side
t-Value
p

pERK1:tERK1 pERK2:tERK2
7
7
1
1.013
0.149
0.024
0.056
0.009
0.408
0.611
0.089
0.176
0.033
0.066
3.238
2.377
0.007
0.035
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